In 2015, Pionyr Immunotherapeutics embarked on a journey to forge a new path in immuno-oncology for patients in need. We are a clinical stage company discovering and developing novel antibody therapeutics that dramatically alter the tumor microenvironment (TME) and enhance the body’s immune defense against cancer – with the potential to eliminate it.
Pionyr's Myeloid Tuning™ cutting-edge technology is based on the discovery that “tuning” the tumor microenvironment to favor immune-activating cells and disable immune-suppressing cells improves the body’s ability to combat cancer, particularly in combination with checkpoint inhibitors. Additionally, Pionyr is building a pipeline of transmembrane and intracellular targets using our cutting-edge technologies and translational assays.
Immuno-oncology is a complex field, which is why Pionyr has recruited a bold and growing team with extensive experience in immunology, immuno-oncology, target discovery, and immunotherapy development. Our “Pionyrs” are banded together by innovation, integrity, team empowerment, respect and one unified voice to translate meaningful science into promising opportunities for treating cancer.
|
|
|
11-50 employees
View all Pionyr Immunotherapeutics employees
|
|
Biotechnology
|
|
2 Tower Pl, Suite 800, South San Francisco, California 94080, US
|
|
2015
|
|
Translational Research, Immuno-Oncology
|
Steve James is the CEO of Pionyr Immunotherapeutics. To contact Steve James email at [email protected] or [email protected]. Or you may call 650 303-9920
The decision makers in Pionyr Immunotherapeutics are Isabel L, Kiren Khanduja, Kristen Pierce, etc. Click to Find Pionyr Immunotherapeutics decision makers emails.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.